Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL

Cell

Volumn 112, Issue 6, 2003, Pages 831-843

  Azam, Mohammad ^a   Latek, Robert R ^a   Daley, George Q ^a,b  

^a WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; IMATINIB; PHOSPHOTRANSFERASE;

ALLOSTERISM; AMINO ACID SUBSTITUTION; ARTICLE; BINDING AFFINITY; CHEMOTHERAPY; CONFORMATION; DRUG RESISTANCE; GENE SEQUENCE; HUMAN; MUTAGENESIS; MUTATION; PRIORITY JOURNAL; RELAPSE;

EID: 0037459344     PISSN: 00928674     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0092-8674(03)00190-9     Document Type: Article

References (49)

1. Barila D., Superti-Furga G. An intramolecular SH3-domain interaction regulates c-Abl activity. Nat. Genet. 18:1998;280-282.
2. Barthe C., Cony-Makhoul P., Melo J.V., Mahon J.R. Roots of clinical resistance to STI-571 cancer therapy. Science. 293:2001;2163.
3. Bradshaw J.M., Mitaxov V., Waksman G. Mutational investigation of the specificity determining region of the Src SH2 domain. J. Mol. Biol. 299:2000;521-535.
4. Branford S., Rudzki Z., Walsh S., Grigg A., Arthur C., Taylor K., Herrmann R., Lynch K.P., Hughes T.P. High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. Blood. 99:2002;3472-3475.
5. Brasher B.B., Roumiantsev S., Van Etten R.A. Mutational analysis of the regulatory function of the c-Abl Src homology 3 domain. Oncogene. 20:2001;7744-7752.
6. Cicchetti P., Ridley A.J., Zheng Y., Cerione R.A., Baltimore D. 3BP-1, an SH3 domain binding protein, has GAP activity for Rac and inhibits growth factor-induced membrane ruffling in fibroblasts. EMBO J. 14:1995;3127-3135.
7. Corbin A.S., Buchdunger E., Pascal F., Druker B.J. Analysis of the structural basis of specificity of inhibition of the Abl kinase by STI571. J. Biol. Chem. 277:2002;32214-32219.
8. Dai Z., Pendergast A.M. Abi-2, a novel SH3-containing protein interacts with the c-Abl tyrosine kinase and modulates c-Abl transforming activity. Genes Dev. 9:1995;2569-2582.
9. Daley G.Q., Baltimore D. Transformation of an interleukin 3-dependent hematopoietic cell line by the chronic myelogenous leukemia-specific P210bcr/abl protein. Proc. Natl. Acad. Sci. USA. 85:1988;9312-9316.
10. Daley G.Q., Van Etten R.A., Baltimore D. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science. 247:1990;824-830.
11. Druker B.J., Sawyers C.L., Kantarjian H., Resta D.J., Reese S.F., Ford J.M., Capdeville R., Talpaz M. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N. Engl. J. Med. 344:2001;1038-1042.
12. Emini E.A. Resistance to anti-human immunodeficiency virus therapeutic agents. Adv. Exp. Med. Biol. 390:1995;187-195.
13. Fainstein E., Einat M., Gokkel E., Marcelle C., Croce C.M., Gale R.P., Canaani E. Nucleotide sequence analysis of human abl and bcr-abl cDNAs. Oncogene. 4:1989;1477-1481.
14. Gishizky M.L., Johnson-White J., Witte O.N. Efficient transplantation of BCR-ABL-induced chronic myelogenous leukemia-like syndrome in mice. Proc. Natl. Acad. Sci. USA. 90:1993;3755-3759.
15. Gonfloni S., Williams J.C., Hattula K., Weijland A., Wierenga R.K., Superti-Furga G. The role of the linker between the SH2 domain and catalytic domain in the regulation and function of Src. EMBO J. 16:1997;7261-7271.
16. Gonfloni S., Frischknecht F., Way M., Superti-Furga G. Leucine 255 of Src couples intramolecular interactions to inhibition of catalysis. Nat. Struct. Biol. 6:1999;760-764.
17. Gonfloni S., Weijland A., Kretzschmar J., Superti-Furga G. Crosstalk between the catalytic and regulatory domains allows bidirectional regulation of Src. Nat. Struct. Biol. 7:2000;281-286.
18. Gorre M.E., Mohammed M., Ellwood K., Hsu N., Paquette R., Rao P.N., Sawyers C.L. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science. 293:2001;876-880.
19. Hantschel O., Nagar B., Guettler S., Kretzschmar J., Dorey K., Kuriyan J., Superti-Furga G. A myristoyl/phosphotyrosine switch regulates c-Abl. Cell. 112:2003;845-857. this issue,
20. Hochhaus A., Kreil S., Corbin A., La Rosee P., Lahaye T., Berger U., Cross N.C., Linkesch W., Druker B.J., Hehlmann R.et al. Roots of clinical resistance to STI-571 cancer therapy. Science. 293:2001;2163.
21. Hofmann W.K., Jones L.C., Lemp N.A., de Vos S., Gschaidmeier H., Hoelzer D., Ottmann O.G., Koeffler H.P. Ph(+) acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation. Blood. 99:2002;1860-1862.
22. Hoover R.R., Mahon F.X., Melo J.V., Daley G.Q. Overcoming STI571 resistance with the farnesyl transferase inhibitor SCH66336. Blood. 100:2002;1068-1071.
23. Huse M., Kuriyan J. The conformational plasticity of protein kinases. Cell. 109:2002;275-282.
24. Kantarjian H.M., Cortes J.E., O'Brien S., Giles F., Garcia-Manero G., Faderl S., Thomas D., Jeha S., Rios M.B., Letvak L.et al. Imatinib mesylate therapy in newly-diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia. high incidence of early complete and major cytogenetic responses Blood. 29:2002;29.
25. Koh E.Y., Chen T., Daley G.Q. Novel retroviral vectors to facilitate expression screens in mammalian cells. Nucleic Acids Res. 30:2002;e142.
26. Li S., Ilaria R.L. Jr., Million R.P., Daley G.Q., Van Etten R.A. The P190, P210, and P230 forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity. J. Exp. Med. 189:1999;1399-1412.
27. Mayer B.J., Baltimore D. Mutagenic analysis of the roles of SH2 and SH3 domains in regulation of the Abl tyrosine kinase. Mol. Cell. Biol. 14:1994;2883-2894.
28. Nagar B., Bornmann W.G., Pellicena P., Schindler T., Veach D.R., Miller W.T., Clarkson B., Kuriyan J. Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). Cancer Res. 62:2002;4236-4243.
29. Nagar B., Hantschel O., Young M.A., Scheffzek K., Veach D., Bornmann W., Clarkson B., Superti-Furga G., Kuriyan J. Structural basis for the autoinhibition of c-Abl tyrosine kinase. Cell. 112:2003;859-871. this issue,
30. Nam H.J., Haser W.G., Roberts T.M., Frederick C.A. Intramolecular interactions of the regulatory domains of the Bcr-Abl kinase reveal a novel control mechanism. Structure. 4:1996;1105-1114.
31. Nicholls A., Sharp K.A., Honig B. Protein folding and association. insights from the interfacial and thermodynamic properties of hydrocarbons Proteins. 11:1991;281-296.
32. Otwinowski Z. Oscillation data reduction program. Sawyer N.I.L., Bailey S. Proceedings of the CCP4 Study Weekend. Data Collection and Processing:1993;SERC Daresbury Laboratory, Warrington, England. 56-62.pp.
33. Panni S., Dente L., Cesareni G. In vitro evolution of recognition specificity mediated by SH3 domains reveals target recognition rules. J. Biol. Chem. 277:2002;21666-21674.
34. Pendergast A.M., Muller A.J., Havlik M.H., Maru Y., Witte O.N. BCR sequences essential for transformation by the BCR-ABL oncogene bind to the ABL SH2 regulatory domain in a non-phosphotyrosine-dependent manner. Cell. 66:1991;161-171.
35. Pluk H., Dorey K., Superti-Furga G. Autoinhibition of c-Abl. Cell. 108:2002;247-259.
36. Roche-Lestienne C., Soenen-Cornu V., Grardel-Duflos N., Lai J.L., Philippe N., Facon T., Fenaux P., Preudhomme C. Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment. Blood. 100:2002;1014-1018.
37. Roumiantsev S., Shah N.P., Gorre M.E., Nicoll J., Brasher B.B., Sawyers C.L., Van Etten R.A. Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop. Proc. Natl. Acad. Sci. USA. 99:2002;10700-10705.
38. Sawyers C.L., Hochhaus A., Feldman E., Goldman J.M., Miller C.B., Ottmann O.G., Schiffer C.A., Talpaz M., Guilhot F., Deininger M.W.et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis. results of a phase II study Blood. 99:2002;3530-3539.
39. Schindler T., Bornmann W., Pellicena P., Miller W.T., Clarkson B., Kuriyan J. Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science. 289:2000;1938-1942.
40. Shah N., Nicoll J., Nagar B., Gorre M., Paquette R., Kuriyan J., Sawyers C. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell. 2:2002;117-125.
41. Shawver L.K., Slamon D., Ullrich A. Smart drugs. tyrosine kinase inhibitors in cancer therapy Cancer Cell. 1:2002;117-123.
42. Thompson J.D., Gibson T.J., Plewniak F., Jeanmougin F., Higgins D.G. The CLUSTAL_X windows interface. flexible strategies for multiple sequence alignment aided by quality analysis tools Nucleic Acids Res. 25:1997;4876-4882.
43. Van Etten R.A., Debnath J., Zhou H., Casasnovas J.M. Introduction of a loss-of-function point mutation from the SH3 region of the Caenorhabditis elegans sem-5 gene activates the transforming ability of c-abl in vivo and abolishes binding of proline-rich ligands in vitro. Oncogene. 10:1995;1977-1988.
44. von Bubnoff N., Schneller F., Peschel C., Duyster J. BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571. a prospective study Lancet. 359:2002;487-491.
45. Wen S.T., Van Etten R.A. The PAG gene product, a stress-induced protein with antioxidant properties, is an Abl SH3-binding protein and a physiological inhibitor of c-Abl tyrosine kinase activity. Genes Dev. 11:1997;2456-2467.
46. Wisniewski D., Lambek C.L., Liu C., Strife A., Veach D.R., Nagar B., Young M.A., Schindler T., Bornmann W.G., Bertino J.R.et al. Characterization of potent inhibitors of the Bcr-Abl and the c-kit receptor tyrosine kinases. Cancer Res. 62:2002;4244-4255.
47. Xu W., Harrison S.C., Eck M.J. Three-dimensional structure of the tyrosine kinase c-Src. Nature. 385:1997;595-602.
48. Xu W., Doshi A., Lei M., Eck M.J., Harrison S.C. Crystal structures of c-Src reveal features of its autoinhibitory mechanism. Mol. Cell. 3:1999;629-638.
49. Young M.A., Gonfloni S., Superti-Furga G., Roux B., Kuriyan J. Dynamic coupling between the SH2 and SH3 domains of c-Src and Hck underlies their inactivation by C-terminal tyrosine phosphorylation. Cell. 105:2001;115-126.